Iovance falls on Wall Street after new doubts about the durability of its experimental lung cancer treatment
Iovance shares plunged on Thursday and lost their 50-day moving average, according to Investor's Business Daily, after new questions emerged about the durability of its experimental lung cancer treatment. The outlet describes Iovance as a top 1% biotech stock.
In 20 seconds
- Iovance fell sharply in Thursday's session.
- The drop took the stock below its 50-day moving average.
- The trigger was new doubts about the durability of its experimental lung cancer treatment.
IASummary generated by artificial intelligence from a story by Investor's Business Daily. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.